DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the...
Category: News
SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name BrexafemmeTM, and granted priority review with a PDUFA target action date...
Summit Therapeutics Announces Rights Offering
Cambridge, MA, March 26, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of business on April 9, 2021. The Company intends to...
Summit Therapeutics Announces Rights Offering
Cambridge, MA, March 26, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of business on April 9, 2021. The Company intends to...
WEP Clinical Expands Availability Of Xenleta® (Lefamulin) Named Patient Program In Partnership With Nabriva Therapeutics
WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA® (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa. NPP is designed to ensure that physicians can request IV or oral XENLETA on behalf of individual patients who have an unmet medical need that...
Entasis Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
– Phase 3 ATTACK registration trial more than three-quarters complete –– ATTACK topline data readout expected second half of 2021 –– Zoliflodacin Phase 3 trial adds clinical trial sites, continues enrollment – WALTHAM, Mass., March 23, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and...
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin)
–Single-Dose Antibiotic with One-Hour Infusion, Additional Compatibilities in Normal Saline and D5W, and Lower Infusion Volume– — Launch Expected in Summer 2021-– MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) — Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration...
Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer
MORRISTOWN, N.J., March 29, 2021 (GLOBE NEWSWIRE) — Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced the appointment of John Harlow as Chief Commercial Officer, effective today. John Harlow, a seasoned pharmaceutical executive, joins Melinta as Chief Commercial Officer under the leadership of President and...
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Cambridge, MA, March 17, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the fourth quarter and full-year ended December 31, 2020. Note: A glossary of terms has been added to the end of this document in...
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Cambridge, MA, March 17, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the fourth quarter and full-year ended December 31, 2020. Note: A glossary of terms has been added to the end of this document in...